Flipping Book - Hema

597 / 1498

Safety and activity of lenalidomide and rituximab in untreated
indolent lymphoma: an open-label, phase 2 trial
Fowler et al Lancet Oncol. 2014 Nov;15(12):15.
Response Rates of R2
SLL (N=30)
Marginal
(N=27)*
Follicular
(N=46)*
All Patients
Eval
(N=103)
ITT
(N=110)
ORR, n (%) 24 (80) 24(89) 45(98) 93(90) 93(85)
CR/Cru 8(27) 18(67) 40(87) 66(64) 66(60)
PR 16(53) 6(22) 5(11) 27(26) 27(25)
SD, n (%) 4(13) 3(11) 1(2) 8(8) 8(7)
PD, n (%) 2(7) 0 0 2(2) 2(2)
*7 pts not evaluable for response:
• 5 due to adverse event in cycle 1
• 1 due to non-compliance
• 1 due to withdrawal of consent